# Ata Dtc Dynamic Risk > ATA DTC Dynamic Risk Stratification Tool - Skill: `dromlakhani/ata-dtc-dynamic-risk` (Agent Skill) - Install (CLI): `npx skillmds@latest add dromlakhani/ata-dtc-dynamic-risk` - Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/ata-dtc-dynamic-risk/raw - Safety review: pending (external: skill-scanner PASS, skillspector PASS) - Works with: Claude Code, Claude.ai, OpenAI Codex - Category: Coding & Dev Tools - Author: dromlakhani (https://skillmd.com/u/dromlakhani) - Updated: 2026-09-21 - Page: https://skillmd.com/skills/dromlakhani/ata-dtc-dynamic-risk --- # ATA DTC Dynamic Risk Stratification Tool **Source:** 2015 ATA Management Guidelines — Response-to-Therapy Classification (Table 13) and Recommendations 56–62. Haugen et al. Thyroid 2016;26(1). DOI: 10.1089/thy.2015.0020 --- ## CONCEPT The initial ATA risk tier (Low/Intermediate/High) is a **static estimate at surgery**. Over time, the patient's actual disease status is better predicted by their **response to therapy** — how Tg, imaging, and anti-Tg antibodies evolve after treatment. Dynamic reclassification replaces the initial tier as the primary driver of: - TSH suppression targets - Follow-up frequency and modality - Need for further therapy --- ## STEP 1 — Timing of Reclassification | Patient Group | When to Reclassify | |---|---| | Post-RAI remnant ablation | 6–12 months after RAI | | Surgery only (no RAI) | 12–24 months after surgery | | Active surveillance PTMC | Reassess at 6–12 months | **Data needed for reclassification:** - [ ] Neck ultrasound (thyroid bed + central + lateral nodes) - [ ] Serum Tg (on suppression OR stimulated if appropriate) - [ ] Anti-Tg antibodies (essential — interferes with Tg interpretation) - [ ] Any additional imaging if clinically indicated --- ## STEP 2 — Classify the Response to Therapy ### ✅ EXCELLENT RESPONSE **Criteria:** - Negative structural and functional imaging (negative neck US, negative whole body scan if performed) - **AND** suppressed Tg **<0.2 ng/mL** (on levothyroxine suppression) - **OR** stimulated Tg **<1 ng/mL** (after withdrawal or rhTSH) - Anti-Tg antibodies undetectable or decreasing to undetectable **Clinical implications:** - Recurrence risk: ~1–4% - TSH target: relax to low-normal (0.5–2.0 mU/L) for all initial risk tiers → low/intermediate risk patients can be managed as euthyroid - Follow-up: reduce intensity — annual clinical exam + TSH/Tg measurement; periodic neck US - No further RAI or additional imaging needed unless new symptoms develop --- ### 📈 BIOCHEMICAL INCOMPLETE RESPONSE **Criteria:** - Negative structural and functional imaging (no structural disease) - **BUT** suppressed Tg **≥1 ng/mL** OR stimulated Tg **≥10 ng/mL** - OR persistently rising anti-Tg antibodies (even with undetectable Tg) **Clinical implications:** - Recurrence risk: ~20% (most are clinically insignificant or spontaneously resolve) - ~30% will develop structural disease; ~20% achieve excellent response without further therapy - **Management options:** - Continue observation with serial Tg + anti-Tg + neck US every 6–12 months - Maintain TSH suppression (target TSH 0.1–0.5 mU/L for intermediate; <0.1 for high) - Consider RAI only if Tg rising significantly (not for stable or declining Tg) - Additional anatomic/functional imaging if Tg acceleration: CT neck/chest, FDG-PET if Tg >10 with negative WBS --- ### 🏗️ STRUCTURAL INCOMPLETE RESPONSE **Criteria:** - Structural or functional evidence of disease persists or is newly identified - Includes: persistent/new lymph nodes on US, residual uptake on WBS, distant metastases on CT/MRI/PET - Tg may be detectable OR undetectable (FDG-avid, RAI-negative disease can have low/undetectable Tg) **Clinical implications:** - Recurrence risk: ~50–85% depending on lesion site and characteristics - Disease-specific mortality 11% for locoregional; up to 57% for distant mets - **Management:** - Additional therapy guided by lesion type, location, size, and pace of progression: - Locoregional resectable disease → surgical re-excision - RAI-avid distant disease → RAI treatment - RAI-refractory disease → kinase inhibitor therapy (sorafenib, lenvatinib) - Slow-growing, asymptomatic distant mets → active surveillance acceptable - Maintain aggressive TSH suppression (TSH <0.1 mU/L) while structural disease present - Multidisciplinary review recommended for high-volume or metastatic cases --- ### ❓ INDETERMINATE RESPONSE **Criteria (any one of the following):** - Nonspecific findings on structural imaging (non-specific US changes, stable non-enlarged nodes) - Faint/equivocal RAI uptake in thyroid bed - Suppressed Tg detectable but **<1 ng/mL** (not clearly excellent) - Stimulated Tg detectable but **<10 ng/mL** - Anti-Tg antibodies stable or declining (not rising, not yet undetectable) **Clinical implications:** - Recurrence risk: ~15–20% - Most indeterminate responses will evolve to excellent or structural over time with serial observation - **Management:** - Continue surveillance with serial neck US + Tg every 6–12 months - TSH target: low-normal to slightly suppressed (0.1–0.5 mU/L for intermediate; 0.5–2 for low risk) - Additional imaging (CT, FDG-PET) if Tg trending upward or new symptoms - Do NOT escalate to additional RAI or surgery without structural evidence of disease --- ## STEP 3 — Map Response to Ongoing TSH Suppression Target | Initial ATA Risk | Current Response | TSH Target | |---|---|---| | Any | Excellent | 0.5–2.0 mU/L (euthyroid range) | | Low | Indeterminate / Biochemical incomplete | 0.1–0.5 mU/L (mildly suppressed) | | Intermediate | Indeterminate / Biochemical incomplete | 0.1–0.5 mU/L | | High | Indeterminate / Biochemical incomplete | <0.1 mU/L | | Any | Structural incomplete | <0.1 mU/L (aggressive suppression) | > **Benefits of TSH suppression must be weighed against harms** (AF, osteoporosis, adrenergic symptoms) especially in elderly, postmenopausal women, and patients with CV disease. --- ## STEP 4 — Reclassification Is Iterative Dynamic risk reclassification is **not a one-time event** — repeat at each follow-up visit: ``` Initial ATA Risk Tier (post-surgery) ↓ First Response Assessment (6–24 months) ↓ [Excellent] → Reduce follow-up intensity, relax TSH suppression [Biochemical incomplete] → Serial Tg/imaging; suppress TSH; consider further workup [Structural incomplete] → Additional therapy decision; MDT review [Indeterminate] → Continue surveillance; follow Tg trend ↓ Re-evaluate at each visit → Update category → Adjust management ``` --- ## CLINICAL GUARDRAILS - **Anti-Tg must be checked every time** — positive anti-Tg invalidates Tg interpretation; track anti-Tg trend as a surrogate marker instead - **Suppressed Tg <0.2 on LT4 is not the same as stimulated Tg <1** — both are criteria for excellent response, but use one or the other consistently; don't mix thresholds - **Rising anti-Tg = biochemical incomplete** — even with undetectable Tg, rising anti-Tg signals disease activity and should be managed as biochemical incomplete - **"Indeterminate" is not "all clear"** — it requires continued follow-up; do not reassign to excellent without meeting all criteria - **Structural incomplete with slow growth** does not always mandate immediate escalation — pace of growth and lesion characteristics guide urgency; active surveillance is reasonable for small, slowly growing, asymptomatic distant lung metastases - **FDG-PET/CT** should be considered when: Tg is rising but RAI WBS is negative (RAI-refractory disease), or when structural disease is clinically suspected but conventional imaging is inconclusive - **Relax TSH suppression in excellent responders** — unnecessary chronic TSH suppression carries cardiovascular and bone risks; excellent response justifies moving to euthyroid range even in initially high-risk patients